"At Baylor Scott & White Research Institute, you are at the heart of everything we do. This philosophy extends to our research, where we focus on breakthroughs that mean something to you—a more accurate diagnosis, a faster recovery or a more effective treatment. Our research brings innovation from our laboratory to your bedside."

During the past decade, Baylor Research Institute conducted 124 clinical trials. In the 10-year time frame, 124 clinical trials started and 64 clinical trials were completed, i.e. on average, 51.6% percent of trials that started reached the finish line to date. In the past 5 years, 49 clinical trials started and 38 clinical trials were completed. i.e. 77.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Baylor Research Institute" #1 sponsor was "Baylor Research Institute" with 20 trials, followed by "Medtronic Cardiac Rhythm and Heart Failure" with 12 trials sponsored, "Icahn School of Medicine at Mount Sinai" with 7 trials sponsored, "Bristol-Myers Squibb" with 5 trials sponsored and "Amgen" with 5 trials sponsored. Other sponsors include 132 different institutions and companies that sponsored additional 112 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Baylor Research Institute" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 14 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 6 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 5 trials as a collaborator, "Baylor Research Institute" with 2 trials as a collaborator and "Baylor University" with 2 trials as a collaborator. Other collaborators include 98 different institutions and companies that were collaborators in the rest 103 trials.

According to Clinical.Site data, the most researched conditions in "Baylor Research Institute" are "Heart Failure" (9 trials), "Atrial Fibrillation" (8 trials), "Rheumatoid Arthritis" (6 trials), "Coronary Artery Disease" (5 trials) and "Glioblastoma" (5 trials). Many other conditions were trialed in "Baylor Research Institute" in a lesser frequency.

Most popular intervention types in "Baylor Research Institute" are "Drug" (89 trials), "Device" (42 trials), "Other" (20 trials), "Biological" (16 trials) and "Procedure" (13 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (30 trials), "Cisplatin" (3 trials), "Nivolumab" (3 trials), "ADI-001" (2 trials) and "Adalimumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Baylor Research Institute" are 179 trials for "All" genders and 6 trials for "Female" genders.

Currently, there are 65 active trials in "Baylor Research Institute". 1 are not yet recruiting, 38 are recruiting, 23 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 95 completed trials in Baylor Research Institute, undefined suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in Baylor Research Institute, 17 "Phase 1" clinical trials were conducted, 45 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 16 trials, and there were also 41 trials that are defined as “Not Applicable".